Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Jaguar Health, Inc. on November 14, 2018. The report serves to announce the Company's third-quarter 2018 results of operations and financial condition. Jaguar Health is an emerging growth company focused on the commercialization and development of Mytesi (crofelemer), its FDA-approved anti-secretory human prescription drug.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been issued in a separate press release (Exhibit 99.1) and will be discussed in a conference call.
Material Changes and Operational Updates
The Company announced current and planned activities regarding:
- Commercial operations for Mytesi.
- Educational initiatives.
- Product development activities.
No specific quantitative material changes versus prior periods are detailed within this 8-K text.
Guidance, Outlook, and Management Commentary
Management scheduled a conference call for November 15, 2018, at 8:00 am ET to discuss the third-quarter results and future plans. The call was accessible via webcast and toll-free dial-in. The filing explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q3 2018 financial figures.
- Listen to the conference call replay for management's detailed commentary on commercial and development progress.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the specific details of the Mytesi product development pipeline mentioned in the press release.